Clinical Trial Update: Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab in ultramutated and hypermutated endometrial cancer has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Yale University | Conditions: Recurrent Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-06-11